ENDOVASC LTD INC
10QSB, EX-27, 2000-11-14
COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Previous: ENDOVASC LTD INC, 10QSB, 2000-11-14
Next: AVIS GROUP HOLDINGS INC, 8-K, 2000-11-14



<TABLE> <S> <C>


<ARTICLE>                     5


<LEGEND>
Exhibit 27

THIS  SCHEDULE  CONTAINS  SUMMARY  FINANCIAL   INFORMATION  EXTRACTED  FROM  THE
CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2000.

</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   3-mos
<FISCAL-YEAR-END>               jun-30-2000
<PERIOD-END>                    sep-30-2000
<CASH>                                  435,660
<SECURITIES>                            0
<RECEIVABLES>                           0
<ALLOWANCES>                            0
<INVENTORY>                             0
<CURRENT-ASSETS>                        435,660
<PP&E>                                  105,194
<DEPRECIATION>                          18,739
<TOTAL-ASSETS>                          698,907
<CURRENT-LIABILITIES>                   1,198,004
<BONDS>                                 0
                   0
                             15
<COMMON>                                14,881
<OTHER-SE>                              (532,375)
<TOTAL-LIABILITY-AND-EQUITY>            698,907
<SALES>                                 0
<TOTAL-REVENUES>                        0
<CGS>                                   0
<TOTAL-COSTS>                           585,573
<OTHER-EXPENSES>                        0
<LOSS-PROVISION>                        0
<INTEREST-EXPENSE>                      29,836
<INCOME-PRETAX>                         (585,573)
<INCOME-TAX>                            0
<INCOME-CONTINUING>                     (585,573)
<DISCONTINUED>                          0
<EXTRAORDINARY>                         0
<CHANGES>                               0
<NET-INCOME>                            (585,573)
<EPS-BASIC>                             (.05)
<EPS-DILUTED>                           (.05)



</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission